Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ubamatamab · 4 trials · 13 indications
Incidence of Treatment emergent adverse events according to NCI CTCAE version 6.0 (Safety and Tolerability)
Objective response rate (ORR): Percentage of patients experiencing complete (CR) or partial response (PR) as the best overall radiological response after 3 cycles of ubamatamab in combination with carboplatin-paclitaxel-bevacizumab based on RECIST 1.1 criteria
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Escalation Phase
Dose Expansion Phase
Dose Expansion Phase
| Arm | Type | Description |
|---|---|---|
| Arm 1A | EXPERIMENTAL | - |
| Arm 1B | EXPERIMENTAL | - |
| Arm 1C | EXPERIMENTAL | - |
| Arm 2A | EXPERIMENTAL | - |
| Arm 2B | EXPERIMENTAL | - |
| Arm 2C | EXPERIMENTAL | - |
| Arm A1 | EXPERIMENTAL | - |
| Arm A2 | EXPERIMENTAL | - |
| Arm B | EXPERIMENTAL | - |
| Arm C | EXPERIMENTAL | - |
| Arm D | EXPERIMENTAL | - |
| Arms E1/E2 | EXPERIMENTAL | - |
| Carboplatin-paclitaxel-bevacizumab + ubamatamab | EXPERIMENTAL | All participants will receive 3 cycles of the combination carboplatin-paclitaxel-bevacizumab + ubamatamab. After the 3 cycles, they will undergo surgery if it is feasible. Subsequently, they will receive maintenance treatment: * ubamatamab + bevacizumab: for participants with BRCA wild-type and HRD negative tumors and for participants with a disease characterized by a BRCA mutation, or HRD positive status, and experiencing stable disease during the chemotherapy * Olaparib + bevacizumab (standard of care): for participants with a disease characterized by a BRCA mutation, or HRD-positive status, and experiencing complete or partial response during the chemotherapy. |
| Monotherapy | EXPERIMENTAL | REGN4018 administration |
| Combination Therapy | EXPERIMENTAL | REGN4018 and cemiplimab administration |
| Name | Type | Description |
|---|---|---|
| Ubamatamab | DRUG | Administered per the protocol |
| Marlotamig | DRUG | Administered per the protocol |
| Sarilumab | DRUG | Administered per the protocol |
| Bevacizumab | DRUG | Administered per the protocol |
| Cemiplimab | DRUG | Administered per the protocol |
| Fianlimab | DRUG | Administered per the protocol |
| PLD | DRUG | Administered per the protocol |
| REGN10597 | DRUG | Administered per the protocol |
| Chemotherapy | DRUG | Carboplatin + Paclitaxel administered at each cycle of 21 days (in total 3 cycles). |
| GCSF | DRUG | Administered at each cycle during the 3 first cycles of the drug combination (chemotherapy + bevacizumab + ubamatamab). |
| Tocilizumab | DRUG | Administered per the protocol |
Key Inclusion Criteria: 1. Has histologically or cytologically confirmed diagnosis of advanced (stage IIIB not amenable to definitive chemoradiotherapy or stage IIIC) or metastatic (stage IV) NSCLC 2. Has received appropriate first line standard of care treatment for advanced or metastatic NSCLC, a...
Top 20 of 83 competitors
Ubamatamab is an investigational bispecific antibody being studied for the treatment of recurrent ovarian cancer, other MUC16-expressing cancers, and advanced or metastatic non-small cell lung cancer. It is also being evaluated in combination with other therapies for platinum-resistant ovarian cancer and as a first-line treatment for ovarian cancer.
Ubamatamab is a bispecific antibody that targets MUC16, a protein expressed on the surface of certain cancer cells. By binding to MUC16, it is designed to direct the immune system to attack and destroy cancer cells that express this protein.
Ubamatamab is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company. Regeneron is conducting multiple clinical trials to evaluate the safety and efficacy of Ubamatamab in various cancer indications.
Ubamatamab is currently in Phase 2 clinical development. It is being studied in Phase 2 trials for recurrent ovarian cancer and non-small cell lung cancer, with additional Phase 1 trials exploring its use in other settings. It is not yet approved by regulatory authorities.
Ubamatamab is being evaluated in several clinical trials, including NCT03564340 (Phase 1, recurrent ovarian cancer and other MUC16+ cancers), NCT06787612 (Phase 2, platinum-resistant ovarian cancer), NCT07154290 (Phase 2, non-small cell lung cancer), and NCT07637851 (Phase 1, first-line ovarian cancer).
Yes, Ubamatamab is also known as REGN4018. In clinical trials, it is sometimes referred to by this alternative name, particularly in earlier studies. Both names refer to the same investigational bispecific antibody being developed by Regeneron.